ARGX ArGEN-X SE

argenx to Present at Upcoming Investor Conferences

argenx to Present at Upcoming Investor Conferences



May 31, 2023



Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in two upcoming investor conferences in June:

  • William Blair 43rd Annual Growth Stock Conference. Presentation on Tuesday, June 6, 2023 at 1:20 p.m. CT in Chicago, IL.



  • Jefferies Healthcare Conference. Fireside chat on Wednesday, June 7, 2023 at 3:00 p.m. ET in New York, NY.



Additional information regarding these events will be available on the Investors section of the argenx website at .

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, the EU and the UK. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on , , and .

For further information, please contact:

Media:

Erin Murphy

Investors:

Beth DelGiacco

Lynn Elton



EN
31/05/2023

Underlying

ARGXArGEN-X SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx to Report First Quarter 2025 Financial Results and Business Upd...

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 May 1, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at . A replay of th...

May 1, 2025 1 EN
Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
TWEKA TKH GROUP N.V. CERT
MRUS MERUS B V
ARGX ARGEN-X SE
AUTL AUTOLUS THERAPEUTICS ADS
AKZA AKZO NOBEL N.V.
DEME DEME GROUP NV
04/28/25 April 28, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
ARGX ARGEN-X SE

argenx FIRST LOOK: Positive CHMP opinion for CIDP

argenx received a positive opinion from the CHMP of the EMA for Vyvgart in treating CIDP in adults with progressive or relapsing disease after prior treatment with corticosteroids or immunoglobulins. The European Commission will now decide on the regulatory submission within 60 days. Vyvgart is the first novel CIDP treatment in over 30 years and could potentially be self-administered. This approval is expected to lead to significant sales in the EU, with EU peak sales estimated at $1.1bn (KBCSe...

04/28/25 April 28, 2025 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa)...

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two months April 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a...

April 28, 2025 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx Announces Annual General Meeting of Shareholders on May 27, 202...

argenx Announces Annual General Meeting of Shareholders on May 27, 2025 April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual General Meet...

April 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch